Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000664981 | SCV002032113 | likely pathogenic | Glycogen storage disease, type II | 2021-08-31 | reviewed by expert panel | curation | The c.2161dupG (p.Glu721GlyfsTer16) variant in GAA is a frameshift variant predicted to cause a premature stop codon in biologically-relevant-exon 16/20, leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). One individual with this variant and Pompe disease has been reported in the literature, but the residual GAA activity and second variant were not provided and therefore PP4 cannot be assessed (PMID: 18425781). Another individual with "p.E721Rfs", identified by newborn screening had been reported (PMIDs 28196920, 29095812) but the cDNA change was not provided. There is a ClinVar entry for this variant (Variation ID: 550277; 1 star review status) with one submitter classifying the variant as likely pathogenic. This variant meets the criteria to be classified as Likely Pathogenic for Pompe disease based on the recommendations of the ClinGen Sequence Variant Interpretation Working Group (https://clinicalgenome.org/site/assets/files/5182/pm2_-_svi_recommendation_-_approved_sept2020.pdf). ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Storage Disorders Expert Panel (Specification Version 2.0): PVS1, PM2_Supporting |
Counsyl | RCV000664981 | SCV000789028 | likely pathogenic | Glycogen storage disease, type II | 2016-12-27 | criteria provided, single submitter | clinical testing |